Abstract
A multicentre double-blind, cross-over trial was planned to evaluate the prophylactic effect of timolol in migraine. The effectiveness of the drug was compared to propranolol and placebo. In the Norwegian part of the trial described in this paper, 18 patients completed the study. The data suggest that timolol is equivalent in effectiveness to propranolol in migraine prophylaxis. Firm conclusions should not be drawn until the results from the multicentre trial are available.

This publication has 7 references indexed in Scilit: